L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH

Hemophagocytic Lymphohistiocytosis Clinical Trial

Official title:

L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV Associated Hemophagocytic Lymphohistiocytosis (HLH)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05315336
• Other study ID #: L-DEP, PD-1, HLH
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: June 1, 2022
• Est. completion date: June 1, 2026

Study information

• Verified date: April 2022
• Source: Beijing Friendship Hospital
• Contact: Zhao Wang
• Phone: 86-010-63139862
• Email: wangzhao[@]ccmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aimed to investigate the efficacy and safety of L-DEP (L-Asparaginasum, liposomal doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment for relapse/refractory EBV associated hemophagocytic lymphohistiocytosis.

Description:

PD-1 antibody added to the DEP regimen （with or without asparaginases） in EBV-HLH

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: June 1, 2026
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 70 Years

Eligibility

Inclusion Criteria:

1. Meet hemophagocytic lymphohistiocytosis (HLH)-04 diagnostic criteria;patients were diagnosed with EBV associated HLH (EBV-HLH).

2. EBV-DNA in peripheral blood or EBER in tissue were positive.

3. Treated with HLH-94 no less than 2 weeks before enrollment and did not achieve at least partial response

4. The patient is expected to be unable to undergo allogeneic hematopoietic stem cell transplantation in the short term due to various reasons (physical status, economic reasons, donor reasons, etc.)

5. The expected survival time is more than 1 month.

6. Age = years old, gender is not limited.

7. Serum creatinine = 1.5 times normal;After infusion, fibrinogen can be corrected to =0.6g/L.

8. Serum human immunodeficiency virus(HIV) antigen or antibody negative; Hepatitis C virus (HCV) antibody is negative, or HCV antibody is positive, but HCV RNA is negative;HBV copies less than 1E+03 copies/ml.

9. The left ventricular ejection fraction (LVEF) was normal.

10. No uncontrollable infection.

11. Contraception for both male or female.

12. Informed consent obtained.

Exclusion Criteria:

1. Allergic to doxorubicin and/or etoposide and/or PD-1 antibody Injection

2. Severe myocardial injury, myocardial enzymes CK, CK-MB increased more than 3 times ULN (upper limit of normal)

3. Heart function above grade II (NYHA).

4. Thyroid dysfunction

5. Serious mental illness;

6. Active hemorrhage of internal organs

7. Previously received L-DEP regimen for HLH-targeted treatment, but the treatment was ineffective or relapsed

8. Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2

9. Participate in other clinical research at the same time.

Related Conditions & MeSH terms

• Hemophagocytic Lymphohistiocytosis
• Lymphohistiocytosis, Hemophagocytic

Intervention

Drug:
• L-DEP and PD-1 antibody
Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.

Locations

Country	Name	City	State
China	Beijing Friendship Hospital, Capital Medical University	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of treatment response	The primary observed endpoint is the objective remission rate (ORR): cases that include complete remission (CR) and partial remission (PR).CR was defined as normalization of all of the quantifiable symptoms and laboratory markers of HLH, including levels of sCD25, ferritin, and triglyceride; hemoglobin; neutrophil counts; platelet counts; and alanine aminotransferase (ALT). PR was defined as at least a 25% improvement in 2 or more quantifiable symptoms and laboratory markers as follows: sCD25 response was>1.5-fold decreased; ferritin and triglyceride decreased at least 25%; for patients with an initial neutrophil count of<0.5 ×109/L, a response was defined as an increase by at least 100% to>0.5× 109/L; for patients with a neutrophil count of 0.5 to 2.0 × 109/L, an increase by at least 100% to >2.0 × 109/L was considered a response; and for patients with ALT >400 U/L, response was defined as an ALT decrease of at least 50%.	Change from before and 2,4,6 and 8 weeks after initiating DEP combine with PD-1 antibody therapy
Secondary	EBV-DNA	Outcome of patients with EBV-HLH	Change from before and 2,4,6 and 8 weeks after initiating DEP combine with PD-1 antibody therapy
Secondary	Survival	Outcome of patients with EBV-HLH	3 months after the intervention
Secondary	Adverse events that are related to treatment	Incidence of events that are related to treatment including myelosuppression, infection, bleeding and so on.	2,4,6 and 8 weeks after initiating DEP combine with PD-1 antibody therapy